Ibogaine is a powerful plant medicine used to treat addiction, but it can disrupt your heart's electrical system and cause dangerous arrhythmias (irregular heartbeats). The FDA (the US drug regulator) publishes formal safety warnings when enough bad cases pile up. This prediction says they'll do that for ibogaine by early 2027. If they do, it will make any legal access to ibogaine much harder and signal serious risk.
FDA has issued safety communications on far thinner adverse-event clustering than what is now accumulating around ibogaine QT prolongation. However, the current political environment (DOGE-era FDA staffing cuts, reduced proactive communications) meaningfully reduces the probability that FDA acts proactively rather than reactively. A formal safety communication is a specific, verifiable action; it is distinct from a press statement or journal editorial. Base rate for FDA safety comms in a 9-month window on a Schedule I substance with no approved use is moderate-low absent a high-profile death in a clinical trial. Confidence reduced to reflect institutional capacity constraints.